Clinical Trial Update: SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR7390 in metastatic hormone-resistant prostate cancer (metastatic castration-resistant prostate cancer) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• SHR7390

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED